Tumor Biology

, Volume 35, Issue 1, pp 111–116 | Cite as

RETRACTED ARTICLE: Curcumin inhibits lung cancer progression and metastasis through induction of FOXO1

  • Zhen-Cai Li
  • Li-Ming Zhang
  • Hai-Bin Wang
  • Jun-Xun Ma
  • Jun-Zhong Sun
Research Article


Recent population studies provide clues that the use of curcumin may be associated with reduced incidence and improved prognosis of certain cancers. In the present study, we demonstrated that curcumin acted as a growth inhibitor for lung cancer cells. Our results found that curcumin inhibited cell proliferation, which was associated with upregulation of the cyclin-dependent kinase inhibitors, p27 and p21, and downregulation of cyclin D1. In addition, we showed that curcumin induced the expression of forkhead box protein O1 (FOXO1) through activation of extracellular signal-regulated kinase 1/2 signaling. These findings provide evidence for a mechanism that may contribute to the antineoplastic effects of curcumin and justify further work to explore potential roles for activators of FOXO1 in the prevention and treatment of lung cancer.


Curcumin Lung cancer FOXO1 ERK1/2 signaling 



This study was supported by the National Natural Science Foundation of China (No. 81071839), Capital Medical Development Foundation of China (2007-2040).

Conflicts of interest



  1. 1.
    Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7:778–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172:523–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, Vansteenkiste JF, et al. Lung cancer: progress in diagnosis, staging and therapy. Respirology. 2010;15:44–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120:2479–87.CrossRefPubMedGoogle Scholar
  5. 5.
    Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002;22:2025–36.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 2002;22:7842–52.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Burgering BM, Medema RH. Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689–701.CrossRefPubMedGoogle Scholar
  8. 8.
    Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 2005;24:7410–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest. 2012;122:2637–51.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Manju V, Nalini N. Chemopreventive efficacy of ginger, a naturally occurring anticarcinogen during the initiation, post-initiation stages of 1,2 dimethylhydrazine-induced colon cancer. Clin Chim Acta. 2005;358:60–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Shehzad A, Khan S, Sup Lee Y. Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol. 2012;8:179–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G. Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res. 2012;32:2567–84.PubMedGoogle Scholar
  13. 13.
    Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher 3rd FJ, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5:230–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Maekawa T, Maniwa Y, Doi T, Nishio W, Yoshimura M, Ohbayashi C, et al. Expression and localization of FOXO1 in non-small cell lung cancer. Oncol Rep. 2009;22:57–64.PubMedGoogle Scholar
  15. 15.
    Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett. 2004;215:129–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med. 2003;49:222–8.PubMedGoogle Scholar
  17. 17.
    Nessa MU, Beale P, Chan C, Yu JQ, Huq F. Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models. Anticancer Res. 2012;32:4843–50.PubMedGoogle Scholar
  18. 18.
    Yogosawa S, Yamada Y, Yasuda S, Sun Q, Takizawa K, Sakai T. Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells. J Nat Prod. 2012;75:2088–93.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Zhen-Cai Li
    • 1
  • Li-Ming Zhang
    • 2
  • Hai-Bin Wang
    • 3
  • Jun-Xun Ma
    • 3
  • Jun-Zhong Sun
    • 3
  1. 1.Department of Ultrasound, The First Affiliated HospitalGeneral Hospital of Chinese PLABeijingChina
  2. 2.No. 535 Hospital of Chinese People’s Liberation ArmyHuaihuaChina
  3. 3.Department of oncology, The First Affiliated HospitalGeneral Hospital of Chinese PLABeijingChina

Personalised recommendations